Evidence map›Paper›PMID 24988316›Full record

ArticlePloS one2014

Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling.

Jan-Peter Sowa, Özgür Atmaca, Alisan Kahraman, Martin Schlattjan, Marion Lindner, Svenja Sydor, Norbert Scherbaum, Karoline Lackner, Guido Gerken, Dominik Heider and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Liver Diseases: Science, Fiction and the Foreseeable Future.Journal of personalized medicine · 2024
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

Jan-Peter SowaDepartment of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany.
Özgür AtmacaDepartment of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany; Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Alisan KahramanDepartment of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany.
Martin SchlattjanDepartment of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany.
Marion LindnerLVR-Clinic, University Hospital, University Duisburg-Essen, Essen, Germany.
Svenja SydorDepartment of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany.
Norbert ScherbaumLVR-Clinic, University Hospital, University Duisburg-Essen, Essen, Germany.
Karoline LacknerInstitute for Pathology, Medical University Graz, Graz, Austria.
Guido GerkenDepartment of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany.
Dominik HeiderDepartment of Bioinformatics, Straubing Center of Science, Straubing, Germany.
Gavin E ArteelDepartment of Pharmacology and Toxicology, University of Louisville Health Sciences Center, Louisville, Kentucky, United States of America.
Yesim ErimLVR-Clinic, University Hospital, University Duisburg-Essen, Essen, Germany; Psychosomatic and Psychotherapeutic Department, University Hospital Erlangen, Erlangen, Germany.
Ali CanbayDepartment of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany.
University of Duisburg-Essen · DEMedical University of Graz · ATUniversitätsklinikum Erlangen · DEUniversity of Louisville · US

Funding

Role of ECM and inflammatory remodeling in alcohol-induced liver and lung damage-diversity supplementR01AA021978 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ARTEEL, GAVIN E · 2014 to 2018
$1.8M
NIAAA NIH HHS R01 AA021978
6 · The paper itself

Abstract

BACKGROUND &

objectiveCurrently, a major clinical challenge is to distinguish between chronic liver disease caused by metabolic syndrome (non-alcoholic fatty liver disease, NAFLD) from that caused by long term or excessive alcohol consumption (ALD). The etiology of severe liver disease affects treatment options and priorities for liver transplantation and organ allocation. Thus we compared physiologically similar NAFLD and ALD patients to detect biochemical differences for improved separation of these mechanistically overlapping etiologies.

methodsIn a cohort of 31 NAFLD patients with BMI below 30 and a cohort of ALD patient with (ALDC n = 51) or without cirrhosis (ALDNC n = 51) serum transaminases, cell death markers and (adipo-)cytokines were assessed. Groups were compared with One-way ANOVA and Tukey's correction. Predictive models were built by machine learning techniques.

resultsNAFLD, ALDNC or ALDC patients did not differ in demographic parameters. The ratio of alanine aminotransferase/aspartate aminotransferase--common serum parameters for liver damage--was significantly higher in the NAFLD group compared to both ALD groups (each p<0.0001). Adiponectin and tumor necrosis factor(TNF)-alpha were significantly lower in NAFLD than in ALDNC (p<0.05) or ALDC patients (p<0.0001). Significantly higher serum concentrations of cell death markers, hyaluronic acid, adiponectin, and TNF-alpha (each p<0.0001) were found in ALDC compared to ALDNC. Using machine learning techniques we were able to discern NAFLD and ALDNC (up to an AUC of 0.9118±0.0056) or ALDC and ALDNC (up to an AUC of 0.9846±0.0018), respectively.

conclusionsMachine learning techniques relying on ALT/AST ratio, adipokines and cytokines distinguish NAFLD and ALD. In addition, severity of ALD may be non-invasively diagnosed via serum cytokine concentrations.

Indexed as

AdipokinesAdiponectinAlanine TransaminaseArtificial IntelligenceAspartate AminotransferasesCohort StudiesComputer SimulationCytokinesFatty Liver, AlcoholicFemaleHumansLiverMaleMiddle AgedModels, BiologicalNon-alcoholic Fatty Liver DiseaseAdipokinesAdiponectinAlanine TransaminaseAspartate AminotransferasesCytokinesTumor Necrosis Factor-alpha

Identifiers

PMID24988316
PMCPMC4079653
OpenAlexW2042762335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.